

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sirnaomics Ltd.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2257)**

**RESIGNATION OF EXECUTIVE DIRECTOR  
AND  
CHANGES TO SENIOR MANAGEMENT**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that the Board has received a letter of resignation from Dr. Michael V. Molyneaux (“**Dr. Molyneaux**”) to resign as an executive Director effective from November 30, 2023, as Dr. Molyneaux wishes to devote more time to his other commitments. Dr. Molyneaux has confirmed that he had no disagreement with the Board and there were no other matters relating to his resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. Dr. Molyneaux has also resigned as the Chief Medical Officer of the Group effective from November 30, 2023.

The Board is pleased to announce that Dr. Francois Lebel (“**Dr. Lebel**”) has been appointed as the Chief Medical Officer of the Group, re-designated from the position of Senior Vice President for preclinical and clinical development effective from December 1, 2023. The biographical details of Dr. Lebel are set out below:

Dr. Lebel is the Chief Medical Officer of the Group and takes a leading role in the Group’s late-stage product development of the innovative RNAi drug candidates. He joined the Group in July 2023 as the Senior Vice President for preclinical and clinical development of the Group. Dr. Lebel is a strategic leader with broad drug development experience including immuno-oncology and nucleic acid therapeutics. Throughout his 30-year solid biopharma industry career with Baxter Healthcare, MedImmune, Chiron Corporation and others, Dr. Lebel has designed and managed international research programs and development organizations to successfully achieve multiple product marketing approvals.

Prior to joining the Group, Dr. Lebel most recently served as the executive vice president for research and development and chief medical officer of Spectrum Pharmaceuticals from November 2018 to January 2023, where he was responsible for preclinical and clinical development, regulatory affairs and pharmacovigilance/drug safety. His commitment to quality and speed of execution resulted in another novel drug product marketing authorization at the U.S. Food and Drug Administration (FDA) in 2022.

Dr. Lebel received his bachelor's degree in molecular biology and a medical degree from the University of Ottawa, Canada, and completed his post graduate training at McGill University and Harvard Medical School. He is Board Certified in Internal Medicine and is a fellow of the Royal College of Physicians of Canada.

The Board would like to take this opportunity to express its sincere gratitude to Dr. Molyneaux for his valuable contribution to the Company during his tenure in office as an executive Director and as the Chief Medical Officer of the Group, and would like to extend its warmest welcome to Dr. Lebel on his new appointment.

By order of the Board  
**Sirnaomics Ltd.**  
**Yang (Patrick) Lu**  
*Chairman and Executive Director*

Hong Kong, November 30, 2023

*As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Xiaochang Dai and Dr. David Mark Evans as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Mr. Fengmao Hua, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.*